Compare IDN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | ANIX |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | United States | United States |
| Employees | 38 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 108.5M |
| IPO Year | 2014 | 2013 |
| Metric | IDN | ANIX |
|---|---|---|
| Price | $3.65 | $3.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.33 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 320.1K | 312.4K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 12.82 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,433,454.00 | $210,000.00 |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $122.33 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $3.61 | $2.32 |
| 52 Week High | $9.08 | $5.46 |
| Indicator | IDN | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 30.64 | 68.10 |
| Support Level | N/A | $2.48 |
| Resistance Level | $4.49 | $4.52 |
| Average True Range (ATR) | 0.15 | 0.27 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 8.44 | 84.31 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.